Research ArticleCancer

Noncoding regions are the main source of targetable tumor-specific antigens

See allHide authors and affiliations

Science Translational Medicine  05 Dec 2018:
Vol. 10, Issue 470, eaau5516
DOI: 10.1126/scitranslmed.aau5516

Expanding the landscape of immunotherapy targets

Most searches for druggable tumor-specific antigens (TSAs) start with an examination of peptides derived from protein-coding exons. Laumont et al. took a different approach and found numerous TSAs aberrantly expressed from noncoding sequences in murine cell lines and in B-lineage acute lymphoblastic leukemia and lung cancer patient samples, but not in cells responsible for T cell selection. The authors validated the immunogenicity and efficacy of TSA vaccination for select antigens in mouse models of cancer. The finding that noncoding regions are a potentially rich source of TSAs could greatly expand the number of targetable antigens across different cancers, including those with low mutational burdens.

View Full Text

Stay Connected to Science Translational Medicine

Editor's Blog